TH MEDICAL-B (ASX: 02697) shares are up more than 9%, with a gain of 8.53% to HK$4.124 at the time of writing, on trading volume of HK$8.446 million.

The company is a robotics firm specializing in percutaneous puncture and ablation surgery. Its core product line consists of four models of percutaneous puncture surgical robots (TH-S1, TH-S, TH-S Pro, and TH-SA), all of which have received Class III registration certificates from China's National Medical Products Administration and are approved for use in lung and abdominal punctures. The company is also working to expand the indications for its TH-S1 model to include retroperitoneal lesions.

According to market research data, the company holds the leading position in China's market for percutaneous puncture surgical robots based on projected 2025 revenue, with a market share of 28.0%.

Potential Inclusion in Southbound Trading Scheme

Market attention is focused on potential index changes. Hang Seng Indexes Company is expected to announce its semi-annual index review results around August 25, with any changes taking effect from September 7. This would prompt corresponding adjustments to the list of eligible stocks for the Southbound Stock Connect scheme. Analysts at Huatai Securities have forecast that TH MEDICAL-B could be included in this scheme.

Financial Performance

From a financial perspective, the company reported revenue of RMB 1.791 million for 2024 and RMB 12.178 million for 2025, representing a year-on-year growth of 579.9% for 2025. This significant growth is primarily attributed to increased sales of its core products.